Comparing Adlai Nortye (NASDAQ:ANL) & Tarsus Pharmaceuticals (NASDAQ:TARS)

Adlai Nortye (NASDAQ:ANL) and Tarsus Pharmaceuticals (NASDAQ:TARS) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, valuation, analyst recommendations, earnings, institutional ownership and profitability.

Insider and Institutional Ownership

35.2% of Adlai Nortye shares are held by institutional investors. Comparatively, 90.0% of Tarsus Pharmaceuticals shares are held by institutional investors. 9.6% of Tarsus Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Risk and Volatility

Adlai Nortye has a beta of 1.23, suggesting that its stock price is 23% more volatile than the S&P 500. Comparatively, Tarsus Pharmaceuticals has a beta of 0.52, suggesting that its stock price is 48% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and recommmendations for Adlai Nortye and Tarsus Pharmaceuticals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adlai Nortye	1	0	3	0	2.50
Tarsus Pharmaceuticals	1	2	4	2	2.78

Adlai Nortye presently has a consensus price target of $21.67, suggesting a potential upside of 96.97%. Tarsus Pharmaceuticals has a consensus price target of $90.67, suggesting a potential upside of 50.96%. Given Adlai Nortye’s higher possible upside, equities research analysts plainly believe Adlai Nortye is more favorable than Tarsus Pharmaceuticals.

Profitability

This table compares Adlai Nortye and Tarsus Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Adlai Nortye	N/A	N/A	N/A
Tarsus Pharmaceuticals	-9.02%	-14.19%	-8.89%

Valuation and Earnings

This table compares Adlai Nortye and Tarsus Pharmaceuticals”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adlai Nortye	$5.00 million	88.00	-$35.53 million	N/A	N/A
Tarsus Pharmaceuticals	$535.08 million	4.83	-$66.42 million	($1.14)	-52.68

Adlai Nortye has higher earnings, but lower revenue than Tarsus Pharmaceuticals.

Summary

Adlai Nortye beats Tarsus Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

About Adlai Nortye

Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule prostaglandin E receptor 4 antagonist to modulate the tumor microenvironment that is in a Phase Ib clinical trial for the treatment of recurrent non-small cell lung cancer and urothelial cancer after anti-PD-1/PD-L1 treatments, recurrent triple-negative breast cancer, microsatellite stable colorectal cancer, and cervical cancer after standard of care treatments; and AN4005, an oral small-molecule PD-L1 inhibitor, which is in Phase I clinical trial to induce and stabilize PD-L1 dimerization and thereby disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include AN8025, a multifunctional antibody as T cell and antigen-presenting cell modulator; AN1025, an oral small molecule degrader of ß-catenin; and AN9025, an oral small molecule pan-KRAS inhibitor. The company was founded in 2004 and is based in Grand Cayman, the Cayman Islands.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.